BACKGROUND: @entity1088 is widely prescribed and, although effective, can cause @entity1017 and dysglycemia. The @entity18948 effects of @entity1088 are thought to be more prevalent in @entity1 with this gender on average attaining 17  % higher plasma @entity1088 concentrations than @entity1 . METHODS: We investigated the relationship between dose, body mass index (BMI), plasma @entity413 concentration, and plasma @entity1088 and @entity30182 ( @entity30182 ) concentrations in 100 individuals with a severe enduring  @entity1032 . RESULTS: Mean (10th/90th percentile) plasma @entity1088 concentrations were higher for @entity1 [0.49 (0.27-0.79) mg/L] compared with @entity1 [0.44 (0.26-0.70) mg/L] (F  =  2.2; p  =  0.035). There was no significant gender difference in the prescribed @entity1088 dose. BMI was significantly higher in @entity1 [mean (95  % CI)  =  34.5 (26.0-45.3)] for females compared with 32.5 (25.2-41.0) for males. Overall, BMI increased by 0.7  kg/m(2) over a mean follow-up period of 210  days. A lower proportion, 41  % of @entity1 had a fasting blood @entity413  <=6.0  mmol/L (<6.0  mmol/L is defined by the International @entity6 Federation as normal @entity413 handling), compared with 88  % of @entity1 (   (2)  =  18.6, p  <  0.0001). CONCLUSIONS: We have shown that mean BMI and blood @entity413 concentrations are higher in @entity1 prescribed @entity1088 than in @entity1 . @entity1 also tended to attain higher plasma @entity1088 concentrations than @entity1 . The higher BMI and blood @entity413 in @entity1 may relate to higher tissue exposure to @entity1088 , as a consequence of sex differences in drug metabolism.

Sex differences in plasma @entity1088 and @entity30182 concentrations in clinical practice and in relation to body mass index and plasma XXXX concentrations: a retrospective survey.

@entity1 :: ('9606', 'Species') :: ['women', 'Women', 'men'] @entity1088 :: ('MESH:D003024', 'Chemical') :: ['Clozapine', 'clozapine'] @entity1032 :: ('MESH:D008607', 'Disease') :: ['mental illness'] @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes'] @entity18948 :: ('MESH:D024821', 'Disease') :: ['dysmetabolic'] @entity1017 :: ('MESH:D015430', 'Disease') :: ['weight gain'] @entity30182 :: ('MESH:C058272', 'Chemical') :: ['N-desmethylclozapine', 'norclozapine'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity413 :: (MESH:D005947,Chemical) :: ['glucose']
